Exenatide vs Pasireotide
Overview
Exenatide is primarily a weight management & metabolic peptide, while Pasireotide is used for hormonal.
This page compares Exenatide and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Exenatide | Pasireotide | |
|---|---|---|
| Category | Weight Management & Metabolic | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 5–10 mcg (Byetta) or 2 mg (Bydureon/Bydureon BCise) | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | Twice daily (Byetta) or once weekly (Bydureon) | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Glycemic control (HbA1c reduction 0.8–1.9 percentage points), modest body weight reduction (2–4 kg), low intrinsic hypoglycemia risk, modest systolic blood pressure reduction, cardiovascular non-inferiority established in EXSCEL | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Nausea, vomiting, diarrhea, injection site reactions, hypoglycemia (when co-administered with sulfonylureas), rare acute pancreatitis, rare acute kidney injury | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. Exenatide is categorised under Weight Management & Metabolic, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Exenatide: FDA-approved. Pasireotide: FDA-approved.
Dosing. Exenatide is typically dosed at 5–10 mcg (Byetta) or 2 mg (Bydureon/Bydureon BCise) (Twice daily (Byetta) or once weekly (Bydureon)). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking Exenatide and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Exenatide and Pasireotide?
- Exenatide is primarily a weight management & metabolic peptide, while Pasireotide is used for hormonal. Exenatide is FDA-approved for one or more indications, whereas Pasireotide is FDA-approved for one or more indications.
- What is Exenatide used for?
- FDA-approved GLP-1 receptor agonist for type 2 diabetes; the first incretin mimetic approved in the US.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take Exenatide and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking Exenatide and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Exenatide or Pasireotide FDA-approved?
- Exenatide is FDA-approved for one or more indications. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- Exenatide — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references